INFOS !
  • NEW ADDRESS: The management team of ERN-EYE is moving! Starting from March 19, you can find us at 1 Rue Eugène Boeckel, 67000 Strasbourg.

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Accessibility

More about accessibility

Trouble using our website?
Contact us

Text logo ERN-EYE Tools
CPMS REDgistry Elearning Members area
Accessibility

Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna) in patients with RPE65-associated inherited retinal degenerations

In this page

Clinical Trial

2021-000265-33 Recruiting, Active
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna) in patients with RPE65-associated inherited retinal degenerations
Interventional

Disease

Disease type

Retinitis Pigmentosa

Inclusion / Exclusion

Opening date

29/01/2021

Inclusion criteria :

More

Exclusion criteria :

More

Funding

Non-Commercial

ERN EYE member investigating site

HCP : Principal investigators

More